MAPT and Alzheimer disease: Furthermore, specific signatures of tau PTMs identified by mass spectrometry in brain tissue and CSF have recently been shown to correlate with clinical heterogeneity and disease severity in AD (Barthélemy et al. 2020; Dujardin et al. 2020; Wesseling et al. 2020).